Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Mr. Jacob Thaysen is the Chief Executive Officer of Illumina Inc, joining the firm since 2023.
What is the price performance of ILMN stock?
The current price of ILMN is $142.54, it has decreased 0.07% in the last trading day.
What are the primary business themes or industries for Illumina Inc?
Illumina Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Illumina Inc market cap?
Illumina Inc's current market cap is $21.6B
Is Illumina Inc a buy, sell, or hold?
According to wall street analysts, 23 analysts have made analyst ratings for Illumina Inc, including 8 strong buy, 6 buy, 13 hold, 2 sell, and 8 strong sell